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Summary
Background The use of methotrexate is limited by interindividual variability in
response. Previous studies in patients with either rheumatoid arthritis or psoriasis
suggest that genetic variation across the methotrexate metabolic pathway might
enable prediction of both efﬁcacy and toxicity of the drug.
Objectives To assess if single nucleotide polymorphisms (SNPs) across four genes
that are relevant to methotrexate metabolism [folypolyglutamate synthase (FPGS),
gamma-glutamyl hydrolase (GGH), methylenetetrahydrofolate reductase (MTHFR)
and 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC)] are
related to treatment outcomes in patients with psoriasis.
Methods DNA was collected from 374 patients with psoriasis who had been treated
with methotrexate. Data were available on individual outcomes to therapy,
namely efﬁcacy and toxicity. Haplotype-tagging SNPs (r
2 >0 Æ8) for the four
genes with a minor allele frequency of > 5% were selected from the HAPMAP
phase II data. Genotyping was undertaken using the MassARRAY spectrometric
method (Sequenom
 ).
Results There were no signiﬁcant associations detected between clinical outcomes
in patients with psoriasis treated with methotrexate and SNPs in the four genes
investigated.
Conclusions Genetic variation in four key genes relevant to the intracellular metabo-
lism of methotrexate does not appear to predict response to methotrexate therapy
in patients with psoriasis.
Methotrexate is a ﬁrst-line systemic therapy for psoriasis; how-
ever, its use is limited by unpredictable efﬁcacy and signiﬁcant
hepatotoxicity and gastrointestinal symptoms. Studies in
patients with psoriasis and rheumatoid arthritis treated with
methotrexate suggest that functional single nucleotide poly-
morphisms (SNPs) in genes relevant to methotrexate metabo-
lism may inﬂuence both efﬁcacy and toxicity of the drug.
1–12
Such studies have focused on isolated functional poly-
morphisms in only a few genes relevant to methotrexate
metabolism and results have been variable, especially in the
most investigated gene methylenetetrahydrofolate reductase
(MTHFR); (Table 1).
We investigated 47 haplotype-tagging and three functional
SNPs in four genes coding for enzymes involved in metho-
trexate intracellular metabolism: folypolyglutamate syn-
thase (FPGS); gamma-glutamyl hydrolase (GGH); MTHFR; and
5-aminoimidazole-4-carboxamide ribonucleotide transformy-
lase (ATIC); (Fig. 1) in a large cohort of patients with psoria-
sis treated with methotrexate.
Methods
This study adheres to the declaration of Helsinki Guidelines
and was approved by the relevant local research ethics com-
mittees. Subjects provided written, informed consent.
Adult patients who had received methotrexate for treatment
of psoriasis were recruited retrospectively from The Dermatol-
ogy Centre, Salford Royal Hospital, Manchester, and St John’s
Institute of Dermatology, London.
Evaluation of efﬁcacy
Patients were stratiﬁed as: (i) ‘responders’––those with clearly
documented clinical improvement, using the Psoriasis Area and
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14 i.e. > 75% reduction in PASI from the
start of methotrexate therapy; and (ii) ‘nonresponders’––those
patients who showed no clear improvement, i.e. < 50%
improvement in PASI while on therapy. In cases where the
PASI score was not recorded, an explicit statement of response
to therapy recorded in the clinical records was acceptable.
Evaluation of toxicity
The adverse effects of methotrexate were assessed by clinical
records:
Hepatotoxicity. Alanine transaminase (ALT) three times the upper
limit of normal on two consecutive outpatient visits and⁄or
serum level of aminoterminal of type III procollagen (P3NP)
elevated above 4Æ2 lgL
)1 on three consecutive occasions or
8Æ0 lgL
)1 on one occasion and⁄or liver biopsy changes con-
sistent with methotrexate hepatotoxicity within 3 years of
starting therapy.
Gastrointestinal. Severe nausea, vomiting or diarrhoea, which
required cessation of methotrexate or the addition of an anti-
emetic.
Bioinformatics
SNPS were located and downloaded from the public HAPMAP
Phase II, October 2005 database (http://www.hapmap.org/).
Haplotype-tagging SNPs (n = 47; r
2 threshold of 0Æ8)
were identiﬁed and ﬁltered through the Haploview software
omitting all markers having a minor allele frequency
< 5%. Additional SNPs previously studied in MTHFR
(rs1801133⁄677C>T and rs1801131⁄298A>C) and ATIC
(rs2372536⁄347C>G) were also genotyped.
Table 1 Summary of previous studies in patients with psoriasis and rheumatoid arthritis (RA) of two single nucleotide polymorphisms
(C677T ⁄rs1801133 and A1298C ⁄rs1801131) in the gene methylenetetrahydrofolate reductase (MTHFR) assessing efﬁcacy and toxicity of
methotrexate (adapted from Hider et al.
13)
Disease Polymorphism No. of patients Efﬁcacy Toxicity Comments Ref.
Psoriasis C677T 202 MM Result for whole cohort, not subgroups 3
RA C677T 236 M › All adverse events + abnormal LFT 1
RA C677T 106 M › 2
RA C677T 93 MM 4
RA C677T 531 MM 11
RA C677T 214 Not reported › CNS adverse event 12
RA C677T 48 ﬂ M 8
RA C677T 205 › M 5
Psoriasis A1298C 202 MM Result for whole cohort, not subgroups 3
RA A1298C 106 › M 2
RA A1298C 93 M › 4
RA A1298C 531 M › 11
RA A1298C 48 M › 8
RA A1298C 205 ›› 5
›, Positive association; M, neutral ﬁnding; ﬂ, negative association. Some studies reported only associations with speciﬁc toxicities such as
abnormal liver function tests (LFT) and central nervous system (CNS) effects.
Fig 1. Illustration of some of the key enzymes involved in the
metabolism of methotrexate (MTX). MTX is transported into the
cell via the solute carrier family 19, member 1 (SLC19A1). It can be
actively transported out of the cell by the ATP-binding cassette
transporters including ATP-binding cassette, subfamily C
(CFTR ⁄MRP), member 1–4 (ABCC1-C4) and ATP-binding cassette,
subfamily G, member 2 (ABCG2). Within the cell it undergoes
polyglutamation (activation) under the enzymic control of
folylpolyglutamate synthase (FPGS). This is a dynamic process where
glutamate residues can be removed by gamma-glutamyl hydrolase
(GGH). In the polyglutamated form MTX inhibits aminoimidazole-4-
carboxamide ribonucleotide transformylase (ATIC), which probably
accounts for some of its anti-inﬂammatory effects via an intracellular
rise in adenosine. Inhibition of the folate pathway may not be as
important to its mechanism of action in psoriasis, but this pathway
includes the enzyme 5,10-methylenetetrahydrofolate reductase
(MTHFR) which has been subject to a number of MTX pharmaco-
genetic studies in the past. MTHFR catalyses the conversion of 5,10-
methylenetetrahydrofolate 5,10-CH2-THF to 5-methyltetrahydofolate
(5-CH3-THF), which is a cosubstrate for homocysteine remethylation.
The polyglutamated form of MTX also inhibits thymidylate synthase
(TYMS), which converts deoxyuridylate (dUMP) to deoxythymidylate
(dTMP) in the de novo pyrimidine biosynthetic pathway. Genes chosen
for this investigation are highlighted in red.
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DNA was extracted from white blood cells using a standard
phenol–chloroform extraction procedure. Fifty SNPs were
genotyped using Sequenom
  MassARRAY  (Sequenom Inc.,
San Diego, CA, U.S.A.) technology.
Statistical analyses
The statistical software package STATA v. 8.2 (StataCorp LP,
College Station, TX, U.S.A.) was used to compare genotype
frequencies (v
2 test for trend) in order to evaluate the associa-
tion of each SNP with each deﬁned treatment outcome. Logis-
tic regression analysis was performed using the software
PLINK
15 to adjust for age of onset of psoriasis, sex, race and,
in 294 of the 374 patients, the presence or absence of folic
acid supplementation.
Results
Patients with chronic plaque psoriasis (n = 374, males 61%,
mean age of onset 24 years) treated with methotrexate were
recruited into the study. Ninety-four per cent of the cohort
was Caucasian and 6% either Chinese or Asian. Folic acid sup-
plementation was being taken by 194 patients with psoriasis;
100 patients received no folate supplementation and data were
unavailable on folic acid use in 80 cases.
Analysis of treatment efﬁcacy was based on 330 patients
who had completed at least 3 months of methotrexate ther-
apy and met the criteria for either ‘responders’ (250
patients) or ‘nonresponders’ (80 patients). Adverse events
had occurred in 177 patients while on methotrexate; 189
patients had ‘no adverse event’. Subgroup analysis of tox-
icity was recorded in 283 patients for hepatotoxicity and in
288 patients for gastrointestinal toxicity. Hepatotoxicity and
gastrointestinal toxicity occurred in 65 and 79 patients,
respectively.
Data were obtained for 50 SNPs in the cohort with a geno-
type success rate of > 90%.
FPGS and GGH
No signiﬁcant (P <0 Æ05) genotypic associations were detected
between SNPs in FPGS or GGH and either the efﬁcacy or tox-
icity of methotrexate. After adjusting for age, sex and ethnicity
the results remained nonsigniﬁcant for all SNPs other than
rs10987746 in FPGS (adjusted P =0 Æ01). No signiﬁcant asso-
ciations were detected upon adjustment for folic acid supple-
mentation.
MTHFR
No signiﬁcant genotypic associations were found between
SNPs in MTHFR and either efﬁcacy or toxicity of methotrexate
before or after adjustment for age, sex, ethnicity and folic acid.
Genotypic data for the previously investigated SNPs rs1801133
and rs1801131 are shown in Table 2. Combined analysis was
performed for SNP rs1801133 T allele and SNP rs1801131 C
allele with no signiﬁcant (P >0 Æ1) association found.
ATIC
No signiﬁcant genotypic associations were detected between
SNPs in ATIC and the efﬁcacy of methotrexate. However, two
of the 15 SNPs were signiﬁcantly (P <0 Æ05) associated with
onset of toxicity (Table 2). The most signiﬁcant of these is the
coding SNP rs2372536, with a v
2 test for trend of P =0 Æ01.
These two SNPs have a very high degree of correlation with
an r
2 of 1 and remain associated with onset of toxicity
(P =0 Æ01) after adjustment for the variables age, sex and
Table 2 Genotypic associations and odds ratios (OR) for the carriage of allele 2 [with 95% conﬁdence interval (CI)] for previously investigated
single nucleotide polymorphisms in the genes methylenetetrahydrofolate reductase (MTHFR) and 5-aminoimidazole-4-carboxamide ribonucleotide
transformylase (ATIC) and their association with the efﬁcacy and toxicity of methotrexate in our psoriasis cohort
Gene ⁄
Rs number
Genotype frequencies (%)
Trend test,
P-value
Carriage of allele 2
OR (95% CI)
Efﬁcacy ⁄toxicity No efﬁcacy ⁄no toxicity
1_1 1_2 2_2 1_1 1_2 2_2
MTHFR
rs1801133 115 (48) 100 (42) 23 (10) 32 (42) 37 (49) 7 (9) 0Æ50 Æ8( 0 Æ4–1Æ4)
rs1801131 118 (51) 86 (37) 28 (12) 40 (54) 28 (38) 6 (8) 0Æ41 Æ1( 0 Æ7–2Æ0)
MTHFR
rs1801133 75 (47) 67 (42) 18 (11) 84 (47) 77 (43) 19 (10) 0Æ90 Æ9( 0 Æ6–1Æ6)
rs1801131 82 (53) 55 (34) 18 (13) 88 (50) 71 (40) 17 (10) 0Æ90 Æ9( 0 Æ6–1Æ4)
ATIC
rs2372536 77 (52) 57 (38) 15 (10) 65 (37) 84 (48) 25 (15) 0Æ01 0Æ6( 0 Æ3–0Æ9)
rs4672768
a 76 (51) 57 (38) 16 (11) 65 (37) 84 (48) 25 (15) 0Æ02 0Æ6( 0 Æ4–0Æ9)
aNo known function but has a borderline association with the onset of toxicity. 1, Major allele; 2, minor allele. Bold font indicates associa-
tion with toxicity.
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with the onset of toxicity after adjustment for the above three
variables. No associations remained after adjusting for folic
acid supplementation. Following correction for the multiple
statistical tests (Bonferroni correction factor, n = 50) these
associations became nonsigniﬁcant (P >0 Æ05). These SNPs
were not associated with either hepatic or gastrointestinal tox-
icity (data not shown).
Discussion
In this study, we found no signiﬁcant (P <0 Æ05) associations
between SNPs in FPGS, GGH and MTHFR and either methotrex-
ate efﬁcacy or toxicity in patients with psoriasis. Borderline
associations (P >0 Æ01 to £ 0Æ05) were detected between
methotrexate toxicity and two SNPs in ATIC. Multivariate anal-
ysis accounting for age at onset of psoriasis, sex and ethnicity
showed four borderline associations between three SNPs in
ATIC and one in FPGS and methotrexate toxicity. When the
Bonferroni correction was performed or when analysing the
subgroups of hepatotoxicity and gastrointestinal toxicity, these
associations became nonsigniﬁcant (P >0 Æ05). Adjustment for
the supplementation with folic acid revealed no associations
between any SNPs and outcomes to methotrexate treatment.
We were unable to replicate any of the previously reported
associations in patients with rheumatoid arthritis and two
functional SNPs in MTHFR and one functional SNP in
ATIC.
1,2,4,6,10,11 No associations were detected for carriage of
combinations of previously described functionally independent
risk alleles in the genes MTHFR (rs1801133 T allele and
rs1801131 C allele) and ATIC (rs2372536 G allele).
Clearly there are important limitations to the current study.
Firstly, it was performed in a retrospective cohort of patients
therefore not allowing a systematic, prospective and objective
collection of phenotypic data. Furthermore, a diverse range of
endpoints was used in studies reported in the literature which
makes direct comparison difﬁcult, particularly as the majority
were performed in patients with rheumatoid arthritis. It is
possible that we may have missed genetic variation across each
of the genes studied which could inﬂuence response to metho-
trexate treatment in psoriasis patients. However, we estimate
that we had 80% gene coverage of all SNPs reported on the
phase II HAPMAP data.
We conclude that genetic variation across the genes FPGS,
GGH, MTHFR and ATIC is not predictive of either efﬁcacy or
toxicity of methotrexate in patients with psoriasis.
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